Bristol-Myers Squibb Company (BMY) vs Vertex Pharmaceuticals Incorporated (VRTX)
BMY leads on 8 of 15 compared metrics.
A side-by-side comparison of Bristol-Myers Squibb Company and Vertex Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of June 13, 2026. The ● marks the stronger figure on each row (cheaper multiple, higher margin/return).
BMY
Bristol-Myers Squibb Company
$57.13Healthcare
VRTX
Vertex Pharmaceuticals Incorporated
$444.93Healthcare
Total return — BMY vs VRTX
growth of $100 · last 30yBMY +171.1%VRTX +2389.1%VRTX compounded faster
Log scale — wide-divergence pair
BMY VRTX
BMY vs VRTX: by the numbers
- •BMY is the larger company ($116.66B vs $112.92B market cap).
- •BMY trades at the lower earnings multiple (16.05 vs 26.39 P/E).
- •VRTX converts more revenue to profit (35.40% vs 15.01% net margin).
- •VRTX grew revenue faster over the past five years (13.82% vs 2.52% CAGR).
- •BMY pays a dividend (4.38% yield) while VRTX does not currently pay one.
Which is better, BMY or VRTX?
Metric tally: BMY 8 · VRTX 7It depends on what you're optimizing for:
ValueBMY(lower P/E)
GrowthVRTX(faster 5Y revenue CAGR)
QualityVRTX(higher ROIC)
Valuation
| Metric | BMY | VRTX |
|---|---|---|
| P/E ratio | 16.05● | 26.39 |
| Forward P/E | 9.31● | 20.58 |
| P/S ratio | 2.41● | 9.31 |
| P/B ratio | 5.82 | 5.89 |
| PEG ratio | 1.71● | 3.23 |
| EV / EBITDA | 11.03● | 20.72 |
| FCF yield | 10.20%● | 3.25% |
Profitability
| Metric | BMY | VRTX |
|---|---|---|
| Gross margin | 68.75% | 86.28%● |
| Operating margin | 25.67% | 38.97%● |
| Net margin | 15.01% | 35.40%● |
| ROE | 36.25%● | 22.41% |
| ROIC | 13.90% | 18.12%● |
Dividends
| Metric | BMY | VRTX |
|---|---|---|
| Dividend yield | 4.38% | — |
| Payout ratio | 72.25% | — |
Growth (annualized)
| Metric | BMY | VRTX |
|---|---|---|
| Revenue CAGR (5Y) | 2.52% | 13.82%● |
| EPS CAGR (5Y) | 9.38%● | 8.17% |
| FCF CAGR (5Y) | -2.50% | 4.01%● |
| Total return CAGR (5Y) | 0.74% | 18.17%● |
Frequently asked
- Which is better, BMY or VRTX?
- It depends on your goal. value: BMY (lower P/E); growth: VRTX (faster 5Y revenue CAGR); quality: VRTX (higher ROIC). Across all compared metrics, BMY leads 8 to 7.
- Is BMY or VRTX cheaper?
- On trailing earnings, BMY is cheaper: BMY trades at a 16.05 P/E and VRTX at 26.39.
- Which has grown faster, BMY or VRTX?
- Over the past five years, VRTX grew revenue faster — BMY at a 2.52% CAGR versus VRTX at 13.82%.
- Does BMY or VRTX pay a bigger dividend?
- BMY pays a dividend (4.38% yield) while VRTX does not currently pay one.
- Is BMY or VRTX more profitable?
- VRTX runs the higher net margin — BMY at 15.01% versus VRTX at 35.40%.
- Which has been the better investment, BMY or VRTX?
- Over the past 10-year, VRTX delivered the higher annualized total return — BMY at 1.08% versus VRTX at 17.13%. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Bristol-Myers Squibb P/E ratioVertex Pharmaceuticals P/E ratioBristol-Myers Squibb dividend yieldVertex Pharmaceuticals dividend yieldBristol-Myers Squibb ROEVertex Pharmaceuticals ROEBristol-Myers Squibb operating marginVertex Pharmaceuticals operating marginBristol-Myers Squibb revenue growthVertex Pharmaceuticals revenue growthBristol-Myers Squibb free cash flowVertex Pharmaceuticals free cash flow
Bristol-Myers Squibb & Vertex Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified June 13, 2026.